Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01775904 · ClinicalTrials.gov registry record · Phase 1
A Study of Two Dosage Forms of LY2886721 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01775904 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 26 participants.
The verdict
NCT01775904, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate two different formulations of LY2886721. In addition, this study will determine how much of study drug (LY2886721) gets into the blood steam and how long the body takes to get rid of it after taking each formulation with or without a meal. Information about any side effects that may occur will also be collected. Each participant may be involved in the study for approximately 7 weeks. This study requires 4 periods. In each period, participants will receive LY2886721 as a tablet or capsule, with or without food and water. There is a 7 day washout between each period.
Interventions
- DRUG LY2886721 in a Capsule
- DRUG LY2886721 in an orally disintegrating tablet (ODT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01775904
The ClinicalTrials.gov registry entry for NCT01775904 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LY2886721 in a Capsule is the first listed.
NCT01775904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01775904 about?
NCT01775904 is a clinical study titled "A Study of Two Dosage Forms of LY2886721 in Healthy Participants". The purpose of this study is to evaluate two different formulations of LY2886721. In addition, this study will determine how much of study drug (LY2886721) gets into the blood steam and how long the body takes to get rid of it after taking each formulation with or without a meal. Information about a...
What is the current status of trial NCT01775904?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2013-02. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01775904?
The interventions under investigation include: LY2886721 in a Capsule (DRUG), LY2886721 in an orally disintegrating tablet (ODT) (DRUG).
Who is sponsoring clinical trial NCT01775904?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.